Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Authors

Jennifer B Green
M Angelyn BethelFollow
Paul W Armstrong
John B Buse
Samuel S Engel
Jyotsna Garg
Robert Josse
Keith D Kaufman
Joerg Koglin
Scott Korn
John M LachinFollow
Darren K McGuire
Michael J Pencina
Eberhard Standl
Peter P Stein
Shailaja Suryawanshi
Frans Van de Werf
Eric D Peterson
Rury R Holman

Document Type

Journal Article

Publication Date

7-16-2015

Journal

The New England Journal of Medicine

Volume

373

Issue

3

Keywords

Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Heart Diseases; Heart Failure; Hemoglobin A, Glycosylated; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Pyrazines; Triazoles

APA Citation

Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., ... & Holman, R. R. (2015). Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 373(3), 232-242.

Peer Reviewed

1